Prognostic impact of neoadjuvant therapy vs upfront surgery in patients with huge hepatocellular carcinoma undergoing curative resection

Table 1 Patient clinical characteristics, n (%)

Variable	Neoadjuvant therapy (n = 56)	Upfront surgery (n = 47)	P value
Age (year)			0.243
< 60	35 (62.5)	24 (51.1)
≥ 60	21 (37.5)	23 (48.9)
Sex
Male	47 (83.9)	41 (87.2)	0.636
Female	9 (16.1)	6 (12.8)
Hypertension			0.588
Absent	39 (69.6)	35 (74.5)
Present	17 (30.4)	12 (25.5)
Diabetes
Absent	50 (89.3)	44 (93.6)
Present	6 (10.7)	3 (6.4)
ASA			0.195
I	35 (62.5)	35 (75.5)
II	21 (37.5)	12 (25.5)
HBV			0.232
Absent	7 (12.5)	10 (21.3)
Present	49 (87.5)	37 (78.7)
HCV			0.238
Absent	52 (92.9)	46 (97.9)
Present	4 (7.1)	1 (2.1)
Hepatocirrhosis			0.662
Absent	10 (17.9)	10 (21.3)
Present	46 (82.1)	37 (78.7)
Tumor number			0.232
Multiple	11 (19.6)	14 (29.8)
Single	45 (80.4)	33 (70.2)
Vascular invasion			0.192
Absent	39 (69.6)	38 (80.9)
Present	17 (30.4)	9 (19.1)
PVTT			0.056
VP0	40 (71.4)	41 (87.1)
VP1	1 (1.8)	0 (0)
VP2	3 (5.4)	4 (8.5)
VP3	12 (21.4)	2 (4.3)
HVTT			0.823
Absent	48 (85.7)	41 (87.2)
Present	8 (14.3)	6 (12.8)
BCLC stage			0.232
A	31 (55.4)	28 (59.6)
B	7 (12.5)	10 (21.3)
C	18 (32.1)	9 (19.1)
HBeAg			0.703
Negative	48 (85.7)	39 (83)
Positive	8 (14.3)	8 (17)
AFP (ng/mL)			0.064
≤ 400	28 (50)	32 (68.1)
> 400	28 (50)	15 (31.9)
Anatomical resection			0.602
Absent	21 (37.5)	20 (42.6)
Present	35 (62.5)	27 (57.4)
Major liver resection			0.803
Absent	24 (42.9)	19 (40.4)
Present	32 (57.1)	28 (59.6)
Surgical method			0.736
Laparoscopy	15 (26.8)	14 (29.8)
Laparotomy	41 (73.2)	33 (70.2)
Adjuvant therapy			0.361
Absent	24 (42.9)	16 (34)
Present	32 (57.1)	31 (66)

ASA: American society of Aneshesiologists; HBV: Hepatitis B virus; HCV: Hepatitis C virus; PVTT: Portal vein tumor thrombosis; HVTT: Hepatic vein tumor thrombus; BCLC: Barcelona Clinic Liver Cancer; HBeAg: Hepatitis B e antigen; AFP: Alpha-fetoprotein.